Seagen Touts Adcetris Early-Stage Lymphoma Data with 93% Complete Remission

Seattle Genetics, known as Seagen, has announced positive results from its Phase II trial for early-stage classical Hodgkin lymphoma. The company reported that Adcetris, in combination with Bristol Myers Squibb’s PD-1 inhibitor and standard chemotherapy agents, led to complete remission in 93% of patients. In Part C of the three-part study, which involved 150 patients, Adcetris showed a 98% over..